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Aims Managed ventricular pacing (MVP) and Search AVþ are representative dual-chamber pacing algorithms for minimizing
ventricular pacing (VP). This randomized, crossover study aimed to examine the difference in ability to reduce per-
centage of VP (%VP) between these two algorithms.
Methods and
results
Symptomatic bradyarrhythmia patients implanted with a pacemaker equipped with both algorithms (Adapta DR,
Medtronic) were enrolled. The%VPs of the patients during two periods were compared: 1 month operation of
either one of the two algorithms for each period. All patients were categorized into subgroups according to the atrio-
ventricular block (AVB) status at baseline: no AVB (nAVB), ﬁrst-degree AVB (1AVB), second-degree AVB (2AVB),
episodic third-degree AVB (e3AVB), and persistent third-degree AVB (p3AVB). Data were available from 127 patients
for the analysis. For all patient subgroups, except for p3AVB category, the median%VPs were lower during the MVP
operation than those during the Search AVþ (nAVB: 0.2 vs. 0.8%, P , 0.0001; 1AVB: 2.3 vs. 27.4%, P ¼ 0.001; 2AVB:
16.4% vs. 91.9%, P ¼ 0.0052; e3AVB: 37.7% vs. 92.7%, P ¼ 0.0003).
Conclusion Managed ventricular pacing algorithm, when compared with Search AVþ, offers further%VP reduction in patients
implanted with a dual-chamber pacemaker, except for patients diagnosed with persistent loss of atrioventricular
conduction.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Transvenous ventricular pacing (VP) has been traditionally per-
formed from the right ventricular apex (RVA) because of the
ease of pacing electrode positioning and the long-term pacing stab-
ility. On the other hand, recently, the adverse effects of pacing at
RVA have rapidly emerged. An increase in cumulative percentage
of RVA pacing in patients treated with pacemakers or implantable
deﬁbrillators results in increased risk of heart failure hospitaliz-
ation, death, and atrial ﬁbrillation (AF).
1–3It is generally considered
that majority of the patients with initially normal left ventricular
(LV) function well tolerate RVA pacing and the detrimental effect
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doi:10.1093/europace/eup252of the pacing predominantly emerges in patients with pre-existing
LV dysfunction,
4 despite the presence of a small study which is
insufﬁciently supportive of these.
5
The detrimental effects of frequent RVA pacing are thought to
be attributable mainly to the ventricular dyssychrony imposed by
RVA pacing, which impairs cardiac pump function.
6 In addition,
an unconsidered short atrioventricular (AV) delay programming
that achieves VP, especially in patients with intact AV conduction,
may compromise active atrial transport and partially contribute
the adverse consequences of frequent RVA pacing.
To avoid or diminish the adverse consequences of RVA pacing,
currently two strategies are proposed. Substituting other VP
site(s), such as right ventricular septum, left ventricle, and
bi-ventricles, for RVA may be a promising approach to attenuate
the adverse effects of pacing-induced ventricular dyssynchrony.
7–9
This approach is somewhat technically challenging and sometimes
costly compared with traditional RVA pacing at present. Moreover,
which site(s) isthe most appropriate for VPas an alternative to RVA
isstillsubjecttoinvestigation.Theotherstrategyinvolvespreserving
normal ventricular activation sequence whenever possible with
manipulation of pacing mode and timing cycle. To implement this
strategy effectively, contemporary dual-chamber pacemakers or
implantable deﬁbrillators are being equipped with new algorithms
for minimizing unnecessary VP.
10–13 Of such algorithms, managed
VP (MVP) which operates in AAI/R mode with backup VP during
AV block (AVB) and Search AVþ which operates in DDD/R mode
with automatic extension of AV interval have been evaluated for
theirclinicalutilityinpatientswithsinus-nodediseaseinalarge-scale
randomized clinical trial.
14 The trial showed that dual-chamber
pacing operating with either one of the two algorithms, when com-
pared with conventional dual-chamber pacing, offered a 40%
reduction in the relative risk of the development of persistent AF
and this was correlated to a reduction in percentage of VP (%VP).
However, how much each dual-chamber minimal VP algorithm
had made contribution to the%VP reduction has not been elabo-
rated. At the same time, the difference in ability to reduce%VP
between the two algorithms has not been well elucidated. The
present multicentre, randomized, crossover study aimed to





Symptomatic bradyarrhythmia patients implanted with a dual-
chamber pacemaker equipped with two types of algorithms for
minimizing VP (Adapta DR, Medtronic Inc., MN, USA) were
selected for enrolment. Patients receiving their ﬁrst pacemaker
as well as those undergoing pacemaker generator replacement
were eligible to participate. Patients were excluded if they had
any of the following: age of 19 or younger, experience symptoms
with the ﬁrst-degree AVB, or inability to comply with study proto-
col. All patients gave written, informed consent to participate in
the study. The study was in compliance with the Declaration of
Helsinki and approved by the ethics committee or the institutional
review board at each of the participant centres.
Device characteristics
Adapta DR is a dual-chamber pacemaker equipped with MVP and
Search AVþ algorithms, each of which is intended to minimize VP.
The MVP operates in atrial-based pacing (AAI/R) with backup VP
during AVB. When AV conduction is lost for two out of four atrial
to atrial depolarization intervals, the pacemaker switches to DDD/
R mode with preprogrammed sensed AV (SAV) and paced AV
(PAV) intervals. Then, the checks for AV conduction are per-
formed. The ﬁrst check occurs 1 min after the switching to
DDD/R mode, and if AV conduction resumes, the pacemaker
switches back to AAI/R mode. If loss of AV conduction persists,
subsequent checks periodically occur until AV conduction
resumes. The time interval for the checks progressively double
(2, 4, 8 min) up to 16 h and then the checks occur every 16 h
thereafter. The Adpata DR does not provide information about
the behaviour of the MVP algorithm between follow-up visits
other than the simple%VP (e.g. how often did AAI/R disengage
to restore DDD/R mode, what were the events that triggered res-
toration of DDD/R mode).
The Search AVþ operates in DDD/R mode as well as in DDI/R,
DVI/R, or VDD mode with automatic extension of PAV and SAV
intervals as needed to promote intrinsic ventricular activation.
Search AVþ uses the ‘Max increase to AV’ parameter to deﬁne
the maximal amount of time by which the operational SAV and
PAV intervals can be automatically extended. For the Adapata
DR pacemaker, SAV and PAV intervals are manually programmable
from 30 to 350 ms in steps of 10 ms, with nominal values of 120
and 150 ms, respectively. ‘Max increase to AV’ is programmable
from 10 to 250 ms in steps of 10 ms, with a nominal value of
170 ms. Therefore, the maximal operational AV intervals can
differ from 40 ms (¼30 þ 10 ms) to 600 ms (¼350 þ 250 ms)
according to the programmed AV intervals and the value of ‘Max
increase to AV’. Search AVþ continuously attempts to adapt the
operational AV intervals to a value slightly longer (15–55 ms)
than AV conduction time. When Search AVþ is turned on, a con-
duction check is automatically started. If AV conduction is not
found within the range of the extendable AV interval and the adap-
tation of operational AV intervals fails, the AV intervals revert to
the programmed values and Search AVþ suspends operation for
progressively longer periods: 15, 30 min, 1, 2, 4, 8, and 16 h.
Unlike MVP, Search AVþ is automatically disabled if no AV con-
duction is found following 10 consecutive 16 h suspicions (1
week). More detailed explanations of MVP and Search AVþ
have been described.
10,11 For the Adapta DR pacemaker, MVP
and Search AVþ cannot be enabled concurrently.
Study design
This study was conducted at 14 centres. Patients enrolled in the
study were randomly assigned to dual-chamber pacing operating
with MVP or Search AVþ algorithm for 1 month and then
crossed over to the alternative algorithm for an additional
month. Either one of the algorithms was turned on at the time
of randomization, 1 week after the pacemaker implantation.
The algorithm switch-overs and ﬁnal data collections were done
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percentage of atrial pacing (%AP), and percentage of time spent
in atrial high rate (%AHR) which is highly likely to represent
atrial tachycardia (AT) or AF burden were obtained from stored
pacemaker diagnostics on completion of 1 month operation for
each algorithm. Patients were categorized into subgroups accord-
ing to the AVB status at baseline: no AVB (nAVB), ﬁrst-degree AVB
(1AVB), second-degree AVB (2AVB), episodic third-degree AVB
(e3AVB), and persistent third-degree AVB (p3AVB). For the
AVB status determination, electrophysiologic testing was not man-
datory and the status was determined based on each participant
clinician’s recognition for the most severe form of AVB of the
patient at the time of randomization. Type I and Type II 2AVB
were categorized with no distinction. Patients presented with 2:1
or more advanced AVB but with intermittent AV conduction
were categorized into e3AVB.
Device programming
The programmed SAV and PAV intervals during DDD/R mode for
MVP or Search AVþ operation and value of ‘Max increase to AV’
for Search AVþ programming in each patient were determined at
the discretion of each participant clinician. Tailorings of other
device parameters that could potentially affect the%VP, such as
rate-adaptive AV, automatic post-ventricular atrial refractory
period, conducted AF response (i.e. ventricular rate regularization
during AF), lead impedance trend which collects lead impedance
data during pacing, and so forth, were also committed to each par-
ticipant clinician.
In this study, Search AVþ was programmed to operate in DDD/
R mode for all patients.
Statistical analysis
Data are presented as mean+standard deviation, median, or fre-
quencies where appropriate. Continuous variables were compared
with the Wilcoxon signed-rank test, whereas comparisons for
categorical variables were performed with the McNemar test.
A probability value of ,0.05 was considered statistically signiﬁcant.
Analyses were performed with SAS statistical software.
Results
Study population
One hundred and forty-one patients were enrolled in the study
between April and December 2008. Of these patients,
13 dropped out from the study, seven because of being lost to
follow-up, two because of symptoms related to MVP or Search
AVþ operation, and remaining four because of the retractions of
participation in the study. One additional patient who had pre-
sented persistent AF throughout the study was removed from
the analysis, despite completion of the two phases of the study.
With the exclusion of these 14 patients, we eventually analysed
the data from 127 patients who successfully completed the cross-
over study. The demographics of these patients are summarized in
Table 1. Of the analysed patients, 106 (83.5%) were enrolled in the
study after undergoing their ﬁrst pacemaker implantation. Three
were indicated a pacemaker implantation for coexistence of
sinus-node disease and AVB. Sixty-four (50.4%) were assigned to
the operating MVP algorithm ﬁrst.
Device programming
Pacemaker parameter settings during the MVP and Search AVþ
operations are summarized in Table 2. The mean programmed
SAV and PAV intervals during DDD/R mode for MVP operation
were 10 ms longer than the nominal values of 120 and 150 ms,
respectively. For the Search AVþ settings, the AV intervals and
‘Max increase to AV’ were programmed to nominal values in 63
(49.6%) patients. Therefore, the maximal operational SAV and
PAV intervals were 290 ms (¼120 þ 170 ms) and 320 ms
(¼150 þ 170 ms), respectively, in these patients. Whereas, in 52
(40.9%) patients, Search AVþ was programmed more aggressively
to permit their maximal operational SAV and PAV intervals being
longer than the nominal settings. The most aggressive Search
AVþ settings observed in the study permitted the SAV and PAV
intervals to extend up to 450 and 500 ms, respectively. In 11
(8.7%) patients, Search AVþ was programmed modestly to
permit their maximal operational SAV and PAV intervals being
shorter than the nominal settings. The shortest maximal oper-
ational SAV and PAV intervals in these patients were 220 and
Table 1 Baseline demographics of the study population
(n 5 127)
Age (years) 76+9
Male gender [n (%)] 52 (40.9)
Underlying disease [n (%)]
a
Coronary artery disease 27 (21.3)
Cardiomyopathy 6 (4.7)
Hypertension 75 (59.1)
Diabetes mellitus 28 (22.0)
CHF history 28 (22.0)
AT/AF history 36 (28.3)
Medication at baseline [n (%)]
a
Beta-blockers 18 (14.2)
Class I/III antiarrhythmics, amiodarone 13 (10.2)
Digoxin 3 (2.4)




Primary pacemaker indication [n (%)]
a
Sinus-node disease 71 (55.9)
AV block 59 (46.5)
AV block grade [n (%)]
None 54 (42.5)
First degree 12 (9.4)
Second degree 14 (11.0)
Episodic third degree 17 (13.4)
Persistent third degree 30 (23.6)
CHF, congestive heart failure; AT, atrial tachycardia; AF, atrial ﬁbrillation; ACE-I,
angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
LVEF, left ventricular ejection fraction; AV, atrioventricular.
aMore than one per patient possible.
bData were available from 92 patients.
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operational SAV and PAV intervals were 290 and 290 ms, respect-
ively. Rate response was enabled in nine (7.1%) patients at the
time of randomization and this setting remained unchanged
throughout the study period in all of these nine patients. The infor-
mation about whether these nine patients had chronotropic
incompetency were not collected. Settings of other parameters
seemed to have remained almost unchanged throughout the
study period.
Percentage of atrial pacing and
percentage of atrial high rate
The median%APs were similar between each operational period
of the two algorithms except for patients categorized into 2AVB.
The median %AHRs were also comparable between each oper-
ational period of the two algorithms across all patient groups
(Table 3).
Difference in percentage of ventricular
pacing between each operational period
of the algorithms
The median%VPs during the MVP operation, when compared with
those during the Search AVþ operation, were signiﬁcantly lower in
the entire study population and all patient subgroups except for
patients categorized into p3AVB (Figure 1). Moreover, the percen-
tages of patients who had %VP ,40 and/or patients who had%VP
,10 during the MVP operation were signiﬁcantly greater com-
pared with those during the Search AVþ operation in the entire
study population and all patient subgroups except for patients
categorized into p3AVB (Table 4).
Adverse events
Two patients dropped out of the study due to symptoms related to
either one operation of the two algorithms, despite completion of
the ﬁrst 1 month phase. One patient, who was categorized into
2AVB,presentedwithchestdiscomfortresultingfromfrequentnon-
conducted atrial depolarization promptly after switching algorithms
from Search AVþ to MVP and was reprogrammed to conventional
DDD. The other patient, who was categorized into e3AVB, pre-
sented with a similar symptom resulting from Wenckebach period-
icity promptly after switching from MVP to Search AVþ was also
reprogrammed to conventional DDD. Additionally, one patient,
who was categorized into p3AVB, experienced mild dizziness
several times during the MVP operation phase but completed both
phases of the study. No other adverse events including sustained
ventricular tachyarrhythmia have been reported.
Discussion
This is the ﬁrst study that assessed the two representative types of
dual-chamber pacing algorithms for minimizing unnecessary VP
with respect to the ability to reduce%VP in the same individuals.
The results demonstrated that the algorithm based on AAI/R
mode with backup VP during AVB of MVP offers further%VP
reduction, when compared with that based on DDD/R mode
with automatic extension of AV interval of Search AVþ. This
ﬁnding was observed in all dual-chamber pacing population
except for patients diagnosed with p3AVB.
................................................................. .....................................................................
...............................................................................................................................................................................
Table 3 Percentage of atrial pacing and %atrial high rate in MVP and Search AV1 operations
Median%AP Median (mean)%AHR
MVP Search AV1 P-value MVP Search AV1 P-value
Total 41.1 35.8 NS 0.0 (2.6) 0.0 (3.5) NS
nAVB 65.8 76.6 NS 0.1 (2.1) 0.0 (2.9) NS
1AVB 72.1 71.8 NS 0.1 (8.1) 0.4 (12.7) NS
2AVB 18.6 13.7 0.002 0.0 (1.0) 0.0 (0.9) NS
e3AVB 18.8 12.4 NS 0.0 (1.4) 0.0 (0.0) NS
p3AVB 11.6 13.2 NS 0.0 (2.8) 0.0 (3.8) NS
%AP, percentage of atrial pacing; %AHR, percentage of time spent in atrial high rate; nAVB, no atrioventricular block; 1AVB, ﬁrst-degree atrioventricular block; 2AVB,
second-degree atrioventricular block; e3AVB, episodic third-degree atrioventricular block; p3AVB, persistent third-degree atrioventricular block; NS, not signiﬁcant.
................................................................................
Table 2 Pacing parameter settings in MVP and Search
AV1 operations
MVP Search AV1
Sensed AV interval (ms) 131+30 131+28
Paced AV interval (ms) 159+26 161+29
Max increase to AV (ms) NA 169+33
Lower rate (bpm) 61+56 0 +5
Upper tracking rate (bpm) 125+7 125+8
Rate response on [n (%)] 9 (7.1) 9 (7.1)
Upper sensor rate (ppm)
a 126+10 126+10
RAAV on [n (%)] 0 (0.0) 0 (0.0)
Automatic PVARP on [n (%)] 127 (100.0) 127 (100.0)
Mode switch on [n (%)] 127 (100.0) 127 (100.0)
Atrial tachyarrythmia detect rate (bpm) 175+1 175+1
Conducted AF response on [n (%)] 0 (0.0) 0 (0.0)
Lead impedance trend on [n (%)] 126 (99.2) 126 (99.2)
AV, atrioventricular; NA, not available; RAAV, rate adaptive AV; PVARP,
post-ventricular atrial refractory period; AF, atrial ﬁbrillation.
aData were obtained from patients with rate response was on.
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rithmic property of MVP or Search AVþ but also by program-
ming of several pacing parameters, ever-changing patient’s
conditions, and interactions of these components. In this study,
the programming of pacemaker parameters that could potentially
affect%VP other than the settings of MVP and Search AVþ
seems not to have been drastically different between MVP and
Search AVþ operation phase. Furthermore, the median%APs in
both phases were similar in all patient groups except for patients
categorized into 2AVB, whereas atrial pacing at the rate that
exceeds intrinsic sinus rate might unmask or deteriorate an
impairment in AV conduction and might increase chance to
trigger VP in some patients.
15 Similarly, the median%AHRs in
both phases were comparable in all patient groups. When
Mode Switch is enabled, spontaneous atrial depolarization at
the rate that exceeds the predeﬁned rate to detect atrial
Figure 1 Comparisons of%VP in each operational period of the two algorithms by patient category: Boxplot graphs denote 90th and 10th
percentiles (whiskers), 75th and 25th percentiles (boxes), medians (horizontal white lines in the boxes), and observations above 90th or below
10th percentile (circles). The values at the bottom of each graph denote median and mean (in parenthesis) %VPs in each operational period of
the two algorithms. nAVB, no AV block; 1AVB, ﬁrst-degree AV block; 2AVB, second-degree AV block; e3AVB, episodic third-degree AV block;
p3AVB, persistent third-degree AV block.
.................................................................. ...................................................................
...............................................................................................................................................................................
Table 4 Percentage of patients who had %VP < 40 and patients who had %VP < 10 in MVP and Search AV1 operations
%VP < 40 (%) %VP < 10 (%)
MVP Search AV1 P-value MVP Search AV1 P-value
Total 66.1 54.3 0.0003 57.5 38.6 ,0.0001
nAVB 100.0 98.1 NS 100.0 79.6 0.0009
1AVB 100.0 66.7 0.0455 75.0 25.0 0.0143
2AVB 64.3 28.6 NS 42.9 7.1 0.0253
e3AVB 52.9 23.5 0.0253 23.5 11.8 NS
p3AVB 0.0 0.0 NS 0.0 0.0 NS
%VP, percentage of ventricular pacing; nAVB, no atrioventricular block; 1AVB, ﬁrst-degree atrioventricular block; 2AVB, second-degree atrioventricular block; 3AVB, persistent
third-degree atrioventricular block; NS, not signiﬁcant.
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tracking mode from atrial tracking mode in patients with impaired
AV conduction. Given the facts mentioned above, we believe that
the results of this study have fewer artefacts.
Comparison with previous studies
Pu ¨rerfellner et al.
16 compared the%VPs in a group of patients
receiving pacing therapy with the Search AVþ operation with
those in another group of patients receiving the therapy with the
MVP operation. As in the present study, they reported the super-
iority of MVP over Search AVþ in terms of%VP reduction except
in the cases with p3AVB. However, the results were derived by the
post hoc analysis of the data obtained from different two
studies,
10,11 while the analysis was performed with well-processed
statistics. On the other hand, the present study prospectively com-
pared the%VPs during the Search AVþ operation and those
during the MVP operation in the same individuals in a crossover
fashion. Furthermore, in the previous study, the AV intervals and
‘Max increase to AV’ those deﬁne the Search AVþ operation
were uniformly programmed to the nominal values. In the
present study, these were programmed at the discretion of the
clinicians and not uniﬁed. The diversity of Search AVþ settings
might be more compliant with clinical practice. Therefore, we
believe that the present study reinforces the results of the previous
study with robust approach.
The SAVE PACe trial
14 showed that the%VP reduction through
either one of the two algorithm operation linked to a risk
reduction of the development of persistent AF over the mean
follow-up of 1.7 years. In the present study, no patient had devel-
oped persistent AF after the enrolment. Moreover, there were no
differences in the %AHR, which is likely to represent AT/AF
burden, between the two phases across all patient groups,
despite the observation of signiﬁcant differences of the %VPs in
most patient groups. We presume that these were attributed to
the shorter study duration and/or the study design that did not
aim to detect the difference in%AHR.
Clinical implications
The present study demonstrated not only that the median%VPs
during the MVP operation were signiﬁcantly lower compared
with those during the Search AVþ operation but also that the per-
centages of patients who had%VP ,40 and/or those who had
%VP ,10 during the MVP operation were signiﬁcantly greater
compared with those during the Search AVþ operation in the
entire patient population and all patient subgroups except for
patients categorized into p3AVB. It has been hypothesized that
the risk of heart failure hospitalization could be reduced if%VP
falls below 40% and the risk could be minimized if %VP falls
below 10% in patients receiving dual-chamber pacing.
1 In the
light of this hypothesis, it is likely that MVP provides more clinical
beneﬁts compared with Search AVþ. However, one question
inevitably arises: MVP may be more prone to impair the ventricular
ﬁlling that is regulated by AV timing, while the algorithm can permit
longer intrinsic AV conduction and maintain ventricular mechanical
synchrony more robustly compared with Search AVþ. Most
recently, Cheng et al.
17 reported that prolongation of the PR inter-
val is associated with increased risk of AF. This ﬁnding seems to
suggest a potential negative effect of the permission for long intrin-
sic AV conduction. Such haemodynamic trade-off may compromise
the advantage of MVP, especially in patients with unusually long
intrinsic AV conduction.
18 Conversely, Search AVþ is able to
establish an upper limit on the magnitude of AV conduction time
and could prevent excessive long intrinsic AV conduction. The
present study has not examined the clinical impact derived from
the difference in%VPs between the two algorithms. Moreover,
no randomized clinical study that investigates the clinical utility of
the algorithms in patients with ﬁrst-degree and intermittent AVB
has been performed. Therefore, it would still be unwise to con-
clude that MVP is superior to Search AVþ in all aspects and con-
siderations should be given based on individual patient assessment
when one applies MVP or Search AVþ, especially to patients with
a signiﬁcant ﬁrst-degree or intermittent AVB at this point.
Managed ventricular pacing allows pauses of up to twice the
lower rate in the event of AVB. Although this algorithmic property
of MVP is apparently more favourable for reducing %VP in patients
with more intermittent AVB (e.g. persistent 2:1 AVB), that may
result in more pauses and related symptoms. In the present
study, three minor adverse symptoms related to either one of
the algorithms were observed. The two were considered as
MVP-related and the remaining one was considered as Search
AVþ-related. This suggests that the incidences of symptoms
related to MVP and Search AVþ may be comparable. On the
other hand, van Mechelen and Schoonderwoerd.
19 have reported
a case presented with a malignant ventricular tachyarrhythmia
related to MVP. Given the previous studies
11,13,20 and the
present study, ventricular tachyarrhythmia events related to MVP
is infrequent. Nevertheless, we hereafter recommend assessing
the potential risk
16 before enabling MVP to avoid such serious
events.
Study limitations
There are several limitations in this study. First, in the present
study, electrophysiologic testing was not mandated for the AVB
status categorization. This might have led some patients who had
latently-impaired AV conduction into nAVB (i.e. intact AV conduc-
tion) category. In clinical practice, however, electrophysiologic
testing is not routinely performed for the triage of patients with
apparent symptomatic bradyarrhythmia. Therefore, we believe
that our approach to categorization of the AVB status was appro-
priate for the consistency with clinical practice. Secondly, the AVB
status in the same individuals could vary over time and this might
have affected the difference in%VPs between the two phases of
the study. To attenuate this potential limitation, we chose a ran-
domized crossover study design. In addition, it has been reported
that the effect of MVP on %VP reduction sustains for at least
6 months even in patients with AVB.
11 This suggests that AVB
status does not alter substantially over 6 months. Relatively short
duration of the present study (i.e. 2 months) also might have
contributed to the attenuation of this potential limitation.
Thirdly, we did not collect the information about changes in medi-
cations, which could have affected the%VP, between the two
phases of the study. However, most patients enrolled in the
study were clinically stable. We believe that there were few, if
any, patients who underwent medication change during the study
Difference in%VP between two algorithms for minimizing VP 101period. Fourthly, the results derived from relatively small patient
subgroups may not apply to larger patient populations. Finally,
we did not evaluate the percentage of ventricular beats that
were fusion or pseudofusion of the VP and intrinsic ventricular
activation. The extent of fusion of VP and intrinsic normal ventri-
cular activation would affect ventricular contraction pattern.
Although pure RVA pacing beat is likely to create abnormal ventri-
cular contraction pattern and deteriorates ventricular function,
fusion or pseudofusion ventricular beat with a near normal QRS
complex would result in near normal ventricular contraction
pattern and is unlikely to affect the cardiac pump function materi-
ally. In theory, Search AVþ, when compared with MVP, could
create more ventricular beats that are fusion of VP and intrinsic
ventricular activation. Therefore, the interpretation of the differ-
ence of%VP between the two algorithms may need to be carefully
applied.
Conclusions
Pacing algorithm for minimizing VP based on AAI/R mode with
backup VP during AVB of MVP, when compared with that based
on DDD/R mode with automatic extension of AV interval of
Search AVþ, offered further%VP reduction in patients implanted
with a dual-chamber pacemaker except for the population diag-
nosed with persistent loss of AV conduction. Moreover, incidence
of adverse symptoms related to both algorithms seemed to be rare
and similar. Nevertheless, the present study has not formally
assessed the clinical impact derived from the difference in%VPs
between the algorithms. Further study will be necessary to dis-
criminate the algorithms in all aspects.
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